676517-01-4

Upstream product

• 336870-02-1 (S)-tert-butoxycarbonylamino-(trans-4-hydroxy-cyclohexyl)-acetic acid 
• 676596-50-2 (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxycyclohexyl)acetate 
• 816421-81-5 [(S)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-1-(4-hydroxy-cyclohexyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Downstream Products

• 676517-03-6 [(S)-1-(3-Bromo-4-oxo-cyclohexyl)-2-((S)-3-fluoro-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 676517-02-5 [(S)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-2-oxo-1-(4-oxo-cyclohexyl)-ethyl]-carbamic acid benzyl ester 
• 815580-99-5 [(S)-1-(3-Bromo-4-oxo-cyclohexyl)-2-((S)-3-fluoro-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid benzyl ester 
• 815581-00-1 [(S)-1-(2-Amino-4,5,6,7-tetrahydro-benzothiazol-6-yl)-2-((S)-3-fluoro-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Heterocycle fused cyclohexylglycine derivatives as novel dipeptidyl peptidase-IV inhibitors

A new class of potent inhibitors of dipeptidyl peptidase IV (DP-IV) for the treatment of type II diabetes are described. Presented herein is the synthesis of indole-fused and thiazole-fused cyclohexylglycines. Pyrrolidine-derived amides of these novel heterocycles led to the discovery of thiazole derivatives (3f) and (11a), both low nanomolar inhibitors of DP-IV (IC50 = 6 nM).